Geen alternatieve tekst opgegeven voor deze afbeelding

The next publication we want to highlight in this #myelomactionmonth is a patient preference study from our #RWE team!

In this study Thomas Wilke and Sabrina Müller collaborated to investigate the preferences of patients with relapsed/refractory MM with novel proteasome inhibitor-based combination treatments using a discrete choice experiment.

They found that patients with RRMM prefer treatments with an all-oral application, a longer PFS, and a lower probability of AE’s. If given the choice patients would accept a lower progression-free time and higher AE rates to get an all-oral therapy.

Read the full publication at: